BRPI0507250A - combinações para tratar desordens do snc - Google Patents
combinações para tratar desordens do sncInfo
- Publication number
- BRPI0507250A BRPI0507250A BRPI0507250-6A BRPI0507250A BRPI0507250A BR PI0507250 A BRPI0507250 A BR PI0507250A BR PI0507250 A BRPI0507250 A BR PI0507250A BR PI0507250 A BRPI0507250 A BR PI0507250A
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- treat
- combinations
- snc
- snc disorders
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- -1 aminomethylpyridyloxymethyl Chemical group 0.000 abstract 2
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 238000011272 standard treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMBINAçãO PARA TRATAR DESORDENS DO SNC Um composto aminometilpiridiloximetil/benzisoxazol subastituído azabicíclico, uma composição farmacêutica do mesmo,e um método de tratar uma ou mais desordem do SNC ou outras desordens, incluindo tratamento corrente e desordens tais como esquizofrenia e depressão.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53993904P | 2004-01-29 | 2004-01-29 | |
PCT/IB2005/000106 WO2005082370A1 (en) | 2004-01-29 | 2005-01-17 | Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0507250A true BRPI0507250A (pt) | 2007-06-26 |
Family
ID=34910687
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0507250-6A BRPI0507250A (pt) | 2004-01-29 | 2005-01-17 | combinações para tratar desordens do snc |
Country Status (7)
Country | Link |
---|---|
US (1) | US20050171086A1 (pt) |
EP (1) | EP1715868A1 (pt) |
JP (1) | JP2007519705A (pt) |
BR (1) | BRPI0507250A (pt) |
CA (1) | CA2555172A1 (pt) |
MX (1) | MXPA06008647A (pt) |
WO (1) | WO2005082370A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050171088A1 (en) * | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
BRPI0514793A (pt) * | 2004-09-10 | 2008-06-24 | Pfizer Prod Inc | uso de derivados azabicìclicos de benzisoxazol e piridiloximetila na preparação de um medicamento para o tratamento de distúrbios cognitivos |
EP1802301A1 (en) * | 2004-10-15 | 2007-07-04 | Pfizer Inc. | Treatment of bipolar disorders and associated symptoms |
US20080132520A1 (en) * | 2006-08-31 | 2008-06-05 | Winsemius Antje A | Compositions, kits and methods for administering a titration schedule comprising bifeprunox compounds |
GB0618879D0 (en) | 2006-09-26 | 2006-11-01 | Zysis Ltd | Pharmaceutical compositions |
EP2170399A1 (en) * | 2007-06-05 | 2010-04-07 | Synthon B.V. | Intranasal administration of asenapine and pharmaceutical compositions therefor |
CN102387704A (zh) * | 2009-02-10 | 2012-03-21 | 雅培制药有限公司 | S1p5受体的激动剂和拮抗剂,和其用法 |
JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
ES2872553T3 (es) | 2015-03-06 | 2021-11-02 | Pharmakea Inc | Inhibidores de lisil oxidasa tipo-2 y usos de los mismos |
SG11201707246YA (en) | 2015-03-06 | 2017-10-30 | Pharmakea Inc | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
MX2019002615A (es) | 2016-09-07 | 2019-10-15 | Pharmakea Inc | Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion. |
MX2019002612A (es) | 2016-09-07 | 2019-08-21 | Pharmakea Inc | Usos de un inhibidor de lisil-oxidasa tipo 2. |
EP3558275A1 (en) | 2016-12-20 | 2019-10-30 | LTS Lohmann Therapie-Systeme AG | Transdermal therapeutic system containing asenapine |
CA3047354A1 (en) | 2016-12-20 | 2018-06-28 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene |
EP3644973B1 (en) | 2017-06-26 | 2021-03-24 | LTS LOHMANN Therapie-Systeme AG | Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer |
AU2018379992B2 (en) | 2017-12-05 | 2022-07-21 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
CN112236138B (zh) | 2017-12-05 | 2024-05-31 | 赛诺维信制药公司 | 晶体形式及其制备方法 |
CN112704672A (zh) | 2018-06-20 | 2021-04-27 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
CN114401717A (zh) | 2019-06-04 | 2022-04-26 | 赛诺维信制药公司 | 修饰释放配制品及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PA8469101A1 (es) * | 1998-04-09 | 2000-09-29 | Pfizer Prod Inc | Ligandos azabiciclicos de receptores 5ht1 |
US20030027817A1 (en) * | 1998-05-29 | 2003-02-06 | Tollefson Gary Dennis | Combination therapy for treatment of bipolar disorders |
UA62015C2 (en) * | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
UA78437C2 (en) * | 2003-03-12 | 2007-03-15 | Pfizer Prod Inc | Azabicyclic derivatives of pyridyloxymethyl and benzisoxazole |
WO2004100992A2 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines |
-
2005
- 2005-01-17 WO PCT/IB2005/000106 patent/WO2005082370A1/en active Application Filing
- 2005-01-17 JP JP2006550332A patent/JP2007519705A/ja not_active Withdrawn
- 2005-01-17 CA CA002555172A patent/CA2555172A1/en not_active Abandoned
- 2005-01-17 BR BRPI0507250-6A patent/BRPI0507250A/pt not_active IP Right Cessation
- 2005-01-17 MX MXPA06008647A patent/MXPA06008647A/es unknown
- 2005-01-17 EP EP05702269A patent/EP1715868A1/en not_active Withdrawn
- 2005-01-28 US US11/048,013 patent/US20050171086A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA06008647A (es) | 2006-09-04 |
JP2007519705A (ja) | 2007-07-19 |
EP1715868A1 (en) | 2006-11-02 |
WO2005082370A1 (en) | 2005-09-09 |
US20050171086A1 (en) | 2005-08-04 |
CA2555172A1 (en) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0507250A (pt) | combinações para tratar desordens do snc | |
ECSP056011A (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol | |
CY1121135T1 (el) | Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος | |
EA202091709A1 (ru) | Ингибиторы днк-пк | |
ATE482209T1 (de) | Verbindungen und zusammensetzungen als modulatoren der gpr119-aktivität | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
WO2007005961A3 (en) | Combinations of eszopiclone and o-desmethylvenlafaxine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders | |
WO2007005962A3 (en) | Combinations of eszopiclone and an antidepressant | |
EA201000603A1 (ru) | ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
DE602006008456D1 (de) | Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen | |
WO2006105516A3 (en) | Compositions and methods for diagnosing and treating neuropsychiatric disorders | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
MX2009009761A (es) | Composiciones y estuches para tratamiento de la influenza. | |
ATE528002T1 (de) | Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
SV2009003212A (es) | Inhibidores de metaloproteasa derivados de heterociclicos ref. prd2727svpct | |
WO2007005940A3 (en) | Combinations of eszopiclone and didesmethylsibutramine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders | |
DK1648484T3 (da) | Fremgangsmåde til behandling af arthritis-tilstande | |
NO20083751L (no) | Metoder for behandling av kognitive og andre sykdommer | |
ATE459353T1 (de) | Gaboxadol zur behandlung von depressionen und anderen affektiven störungen | |
BR112021022380A2 (pt) | Inibidores de jak |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A E 6A ANUIDADES |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011. |